Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AMLX with free AI briefings, catalyst countdowns, and dilution alerts.

AMLX · Amylyx Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$768.1M Cash on Hand
70.8mo Cash Runway
Follow AMLX by email Get an email when AMLX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AMLX, unsubscribe in one click. Privacy

📣 What AMLX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
AMX0035 Progressive Supranuclear Palsy Phase 2/3 · NCT06122662 Completed
Avexitide Post Bariatric Hypoglycemia Phase 3 · NCT06747468 Active not recruiting
AMX0114 ALS Phase 1 · NCT06665165 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AMLX holds $768.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $32.5M/quarter from operations, an estimated runway of 70.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 17 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMLX files for a raise →

👥 Who Owns AMLX

Insiders 6.7% Other 5%+ holders 4.9% Institutions (300 holders) 88.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 16,468,419 12.81% 2025-12-31
Perceptive Advisors LLC Institution (13G, 5%+) 10,573,735 8.22% 2026-09-30
BlackRock, Inc. Institution (13G, 5%+) 7,783,648 6.05% 2025-12-31
TCG Crossover GP II, LLC 5%+ holder (13G) 6,243,812 4.86% 2025-12-31
Joshua B Cohen
Co-Chief Executive Officer, Director · +373,295 options
Insider 3,513,123 2.73% 2026-11-09
Justin B. Klee
Co-Chief Executive Officer, Director · +373,295 options
Insider 3,513,056 2.73% 2026-11-09
George M Jr Milne
Director · +24,372 options
Insider 782,881 0.61% 2026-10-05
Camille L Bedrosian
Chief Medical Officer · +143,985 options
Insider 278,064 0.22% 2026-09-10
James M Frates
Chief Financial Officer · +467,820 options
Insider 273,625 0.21% 2026-11-09
Gina Mazzariello
Chief Legal Officer · +111,990 options
Insider 190,838 0.15% 2026-09-10
Karen Firestone
Director · +24,372 options
Insider 116,900 0.09% 2026-08-31

Share count 128,562,904 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AMLX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMLX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.